RESUMEN
BACKGROUND: Each year, approximately 1.1 million children are exposed in utero to human immunodeficiency virus antiretrovirals, yet their safety is often not well characterized during pregnancy. The Tsepamo study reported a neural tube defect signal in infants exposed to the integrase strand transfer inhibitor (InSTI) dolutegravir from conception, suggesting that exposure during early fetal development may be detrimental. METHODS: The effects of InSTIs on 2 human embryonic stem cell (hESC) lines were characterized with respect to markers of pluripotency, early differentiation, and cellular health. In addition, fetal resorptions after exposure to InSTIs from conception were analyzed in pregnant mice. RESULTS: At subtherapeutic concentrations, second-generation InSTIs bictegravir, cabotegravir, and dolutegravir decreased hESC counts and pluripotency and induced dysregulation of genes involved in early differentiation. At therapeutic concentrations, bictegravir induced substantial hESC death and fetal resorptions. It is notable that first-generation InSTI raltegravir did not induce any hESC toxicity or differentiation, at any concentration tested. CONCLUSIONS: Exposure to some InSTIs, even at subtherapeutic concentrations, can induce adverse effects in hESCs and pregnant mice. Given the increasingly prevalent use of second-generation InSTIs, including in women of reproductive age, it is imperative to further elucidate the effect of InSTIs on embryonic development, as well as their long-term safety after in utero exposure.
Asunto(s)
Infecciones por VIH , Inhibidores de Integrasa VIH , Células Madre Embrionarias Humanas , Exposición Materna , Animales , Femenino , Humanos , Ratones , Embarazo , Farmacorresistencia Viral/genética , Reabsorción del Feto/inducido químicamente , Reabsorción del Feto/tratamiento farmacológico , Compuestos Heterocíclicos con 3 Anillos/toxicidad , Compuestos Heterocíclicos de 4 o más Anillos/farmacología , Infecciones por VIH/tratamiento farmacológico , Inhibidores de Integrasa VIH/toxicidad , Células Madre Embrionarias Humanas/metabolismo , Piridonas/uso terapéutico , Raltegravir Potásico/toxicidad , Recién NacidoRESUMEN
Dolutegravir (DTG) is currently one of the most used Integrase inhibitors (INI) in antiretroviral therapies (ARV) in both naïve and experienced people living with HIV (PLWHIV). We analyzed a multicenter cohort of PLWHIV, both naïve and experienced, starting an ARV including DTG. We enrolled 3775 PLWHIV: 2763 (73.2%) were males, with a median age of 50 years. During 9890.7 PYFU, we observed 930 discontinuations (9.4 per 100 PYFU). Estimated probabilities of maintaining DTG at three and five years were 75.1% and 67.2%, respectively. Treatment-naïve pts showed a lower probability of maintaining DTG at three and five years compared to treatment-experienced PLWHIV (log-rank p < 0.001). At a multivariate analysis, a longer time of virological suppression (aHR 0.994, p < 0.001) and having experienced a previous virological failure (aHR 0.788, p = 0.016) resulted protective against DTG discontinuation. Most discontinuations (84.0%) happened within the first 12 months of DTG initiation, in particular, 92.2% of discontinuations due to neuropsychiatric toxicity were observed in the first year. Our data confirm the overall good tolerability of DTG in clinical practice, with a low rate of discontinuations. CNS toxicity resulted the main reason for DTG discontinuation, with most related interruptions happening in the first year from DTG introduction.
Asunto(s)
Tolerancia a Medicamentos , Infecciones por VIH/tratamiento farmacológico , Inhibidores de Integrasa VIH/toxicidad , Compuestos Heterocíclicos con 3 Anillos/toxicidad , Oxazinas/toxicidad , Piperazinas/toxicidad , Piridonas/toxicidad , Adulto , Fármacos Anti-VIH/uso terapéutico , Fármacos Anti-VIH/toxicidad , Estudios de Cohortes , Femenino , Infecciones por VIH/epidemiología , Compuestos Heterocíclicos con 3 Anillos/uso terapéutico , Humanos , Italia/epidemiología , Masculino , Persona de Mediana Edad , Oxazinas/uso terapéutico , Piperazinas/uso terapéutico , Piridonas/uso terapéuticoRESUMEN
Dolutegravir (DTG) is an antiretroviral drug of the integrase strand transfer inhibitor (INSTI) class used to treat human immunodeficiency virus infection. It is the recommended first-line regimen for most people, including women of childbearing age. However, some human and animal studies have suggested that DTG causes birth defects, although its developmental toxicity remains controversial. Here, we investigated the adverse effects of DTG using pluripotent stem cell-based in vitro morphogenesis models that have previously been validated as effective tools to assess the developmental toxicity of various chemicals. DTG diminished the growth and axial elongation of the morphogenesis model of mouse pluripotent stem cells at exposures of 2 µM and above in a concentration-dependent manner. Concomitantly, DTG altered the expression profiles of developmental regulator genes involved in embryonic patterning. The adverse effects were observed when the morphogenesis model was exposed to DTG at early stages of development, but not at later stages. The potency and molecular impact of DTG on the morphogenesis model were distinct from other INSTIs. Last, DTG altered the growth and gene expression profiles of the morphogenesis model of human embryonic stem cells at 1 µM and above. These studies demonstrate that DTG impairs morphological and molecular aspects of the in vitro morphogenesis models in a manner dependent on dose and timing of exposure through mechanisms that are unrelated to its action as an INSTI. This finding will be useful for interpreting the conflicting outcomes regarding the developmental toxicity of DTG in human and animal studies.
Asunto(s)
Inhibidores de Integrasa VIH , Animales , Femenino , Inhibidores de Integrasa VIH/uso terapéutico , Inhibidores de Integrasa VIH/toxicidad , Compuestos Heterocíclicos con 3 Anillos/toxicidad , Humanos , Ratones , Morfogénesis , Oxazinas , Piperazinas , Piridonas , Células MadreRESUMEN
OBJECTIVE: Maternal folate (vitamin B9) status is the largest known modifier of neural tube defect risk, so we evaluated folate-related mechanisms of action for dolutegravir (DTG) developmental toxicity. DESIGN: Folate receptor 1 (FOLR1) was examined as a target for DTG developmental toxicity using protein and cellular interaction studies and an animal model. METHODS: FOLR1 competitive binding studies were used to test DTG for FOLR1 antagonism. Human placenta cell line studies were used to test interactions with DTG, folate, and cations. Zebrafish were selected as an animal model to examine DTG-induced developmental toxicity and rescue strategies. RESULTS: FOLR1 binding studies indicate DTG is a noncompetitive FOLR1 antagonist at therapeutic concentrations. In-vitro testing indicates calcium (2âmmol/l) increases FOLR1-folate interactions and alters DTG-FOLR1-folate interactions and cytotoxicity. DTG does not inhibit downstream folate metabolism by dihydrofolate reductase. Early embryonic exposure to DTG is developmentally toxic in zebrafish, and supplemental folic acid can mitigate DTG developmental toxicity. CONCLUSION: Folates and FOLR1 are established modifiers of risk for neural tube defects, and binding data indicates DTG is a partial antagonist of FOLR1. Supplemental folate can ameliorate increased developmental toxicity due to DTG in zebrafish. The results from these studies are expected to inform and guide future animal models and clinical studies of DTG-based antiretroviral therapy in women of childbearing age.
Asunto(s)
Receptor 1 de Folato/antagonistas & inhibidores , Ácido Fólico/administración & dosificación , Compuestos Heterocíclicos con 3 Anillos/toxicidad , Proteínas de Pez Cebra/antagonistas & inhibidores , Pez Cebra/embriología , Animales , Línea Celular , Suplementos Dietéticos , Desarrollo Embrionario/efectos de los fármacos , Femenino , Receptor 1 de Folato/genética , Infecciones por VIH/tratamiento farmacológico , Inhibidores de Integrasa VIH/toxicidad , Humanos , Modelos Animales , Oxazinas , Piperazinas , Embarazo , Piridonas , Pruebas de Toxicidad , Pez Cebra/genética , Proteínas de Pez Cebra/genéticaRESUMEN
CONTEXT: Acquired immunodeficiency syndrome (AIDS) is a serious health problem worldwide. It has been reported that Aglaia andamanica Hiern (Meliaceae) leaves possessed an antiviral effect. Therefore, a search of anti-HIV-1 integrase (HIV-1 IN) agents from A. andamanica is a promising target. OBJECTIVE: The objective of this study is to evaluate anti-HIV-1 IN activity of isolated compounds from A. andamanica using an in vitro assay and molecular docking study as well as testing acute toxicity in mice using the up and down method. MATERIALS AND METHODS: The leaves and compounds (3-100 µg/mL) from A. andamanica were determined for the anti-HIV-1 IN effect using the multiplate integration assay (MIA) by detection the absorbance of the final product, p-nitrophenol, at 405 nm. The molecular docking with the HIV-1 IN of the active compound N-methyl-trans-4-hydroxy-l-proline (10) was also studied. The Swiss albino mice were used for an acute toxicity test. RESULTS AND DISCUSSION: Among the isolated compounds, 10 showed marked anti-HIV-1 IN effect with an IC50 value of 11.8 µg/mL, whereas other compounds were inactive (IC50 value > 100 µg/mL). The molecular docking of compound 10 with an HIV-1 IN enzyme was also studied. The result revealed that this compound formed the hydrogen bonding with the Thr66, Asn155, and Lys159 of the HIV-1 IN binding site. The acute toxicity of the A. andamanica extract was not observed at the dose 2000 mg/kg mice. This is the first report of A. andamanica for anti-HIV-1 IN activity.
Asunto(s)
Aglaia , Inhibidores de Integrasa VIH/metabolismo , VIH-1/efectos de los fármacos , Simulación del Acoplamiento Molecular/métodos , Extractos Vegetales/metabolismo , Pruebas de Toxicidad Aguda/métodos , Animales , Femenino , Integrasa de VIH/metabolismo , Inhibidores de Integrasa VIH/aislamiento & purificación , Inhibidores de Integrasa VIH/toxicidad , VIH-1/enzimología , Masculino , Ratones , Extractos Vegetales/aislamiento & purificación , Extractos Vegetales/toxicidad , Hojas de la PlantaRESUMEN
Although a number of anti HIV drugs have been approved, there are still problems with toxicity and drug resistance. This demonstrates a need to identify new compounds that can inhibit infection by the common drug resistant HIV-1 strains with minimal toxicity. Here we describe an efficient assay that can be used to rapidly determine the cellular cytotoxicity and efficacy of a compound against WT and mutant viral strains. The desired target cell line is seeded in a 96-well plate and, after a 24 hr incubation, serially dilutions of the compounds to be tested are added. No further manipulations are necessary for cellular cytotoxicity assays; for anti HIV assays a predetermined amount of either a WT or drug resistant HIV-1 vector that expresses luciferase is added to the cells. Cytotoxicity is measured by using an ATP dependent luminescence assay and the impact of the compounds on infectivity is measured by determining the amount of luciferase in the presence or the absence of the putative inhibitors. This screening assay takes 4 days to complete and multiple compounds can be screened in parallel. Compounds are screened in triplicate and the data are normalized to the infectivity/ATP levels in absence of target compounds. This technique provides a quick and accurate measurement of the efficacy and toxicity of potential anti HIV compounds.
Asunto(s)
Inhibidores de Integrasa VIH/farmacología , Integrasa de VIH/metabolismo , Transcriptasa Inversa del VIH/antagonistas & inhibidores , Inhibidores de la Transcriptasa Inversa/farmacología , Línea Celular Tumoral , Evaluación Preclínica de Medicamentos/métodos , Células HEK293 , Inhibidores de Integrasa VIH/toxicidad , Transcriptasa Inversa del VIH/metabolismo , VIH-1/enzimología , Humanos , Concentración 50 Inhibidora , Inhibidores de la Transcriptasa Inversa/toxicidadRESUMEN
A series of 5,6-dihydroxypyrimidine analogs were synthesized and evaluated for their anti-HIV activity in vitro. Among all of the analogs, several compounds exhibited significant anti-HIV activity, especially 1b and 1e, which showed the most potent anti-HIV activity with EC(50) values of 0.14 and 0.15 µM, and TI (therapeutic index) values of >300 and >900, respectively. Further docking studies revealed that the representative compounds 1e and 3a could meet the HIV-1 integrase inhibition minimal requirements of a chelating domain (two metal ions) and an aromatic domain (π-π stacking interactions).
Asunto(s)
Inhibidores de Integrasa VIH/química , Integrasa de VIH/química , VIH-1/enzimología , Pirimidinas/química , Sitios de Unión , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Integrasa de VIH/metabolismo , Inhibidores de Integrasa VIH/síntesis química , Inhibidores de Integrasa VIH/toxicidad , VIH-1/efectos de los fármacos , Humanos , Simulación del Acoplamiento Molecular , Estructura Terciaria de Proteína , Pirimidinas/síntesis química , Pirimidinas/toxicidad , Relación Estructura-ActividadRESUMEN
HIV-1 integrase inhibitors (INIs) are a promising class of antiretrovirals for the treatment of HIV in adults; there is interest in expanding their use into pediatric populations. A theoretical concern for developmental immunotoxicity was raised after a publication suggested that two HIV INI tool compounds inhibited in vitro cleavage activity of recombination activating genes 1 and 2 (RAG1/2) through the inhibition of their binding to recombination signal sequences. RAG1/2 are required for the development of mature B and T lymphocyte populations. The potential effects of the investigational INI dolutegravir on RAG1/2 were addressed by developing assays in juvenile rats to measure T cell receptor (TCR) Vß usage by flow cytometry as an indicator of TCR repertoire diversity and a T cell dependent antibody response (TDAR) as an indicator of immunosuppression. These endpoints were incorporated into a juvenile rat toxicity study, along with immunophenotyping, hematology, and histopathology of immunologic organs. Dose levels of 0, 0.5, 2, or 75mg/kg/day dolutegravir were given via oral gavage from postnatal day 4 through 66. At the highest dose, there was decreased body weight gain and two preweanling deaths; however, there were no treatment-related effects on developmental parameters. There were no effects on immunologic competence, as measured by TDAR, and no effects on lymphocyte subsets or CD4 and CD8 TCR Vß usage in peripheral blood. Histopathology of immunologic organs (spleen, thymus, lymph nodes) and hematology evaluation revealed no effects. The no observed adverse effect level for immunotoxicity endpoints was 75mg/kg/day.
Asunto(s)
Crecimiento y Desarrollo/efectos de los fármacos , Inhibidores de Integrasa VIH/toxicidad , Compuestos Heterocíclicos con 3 Anillos/toxicidad , Sistema Inmunológico/efectos de los fármacos , Sistema Inmunológico/crecimiento & desarrollo , Inmunidad Innata/efectos de los fármacos , Administración Oral , Animales , Animales Recién Nacidos , Relación Dosis-Respuesta a Droga , Femenino , Crecimiento y Desarrollo/inmunología , Pruebas Hematológicas , Sistema Inmunológico/inmunología , Inmunidad Innata/inmunología , Inmunidad Innata/fisiología , Inmunocompetencia/efectos de los fármacos , Inmunocompetencia/inmunología , Inmunofenotipificación , Terapia de Inmunosupresión , Ganglios Linfáticos/efectos de los fármacos , Ganglios Linfáticos/patología , Masculino , Oxazinas , Piperazinas , Piridonas , Receptores de Antígenos de Linfocitos T alfa-beta/efectos de los fármacos , Receptores de Antígenos de Linfocitos T alfa-beta/metabolismo , Medición de Riesgo , Bazo/efectos de los fármacos , Bazo/patología , Subgrupos de Linfocitos T/efectos de los fármacos , Subgrupos de Linfocitos T/inmunología , Timo/efectos de los fármacos , Timo/patología , Aumento de Peso/efectos de los fármacosRESUMEN
The objective of this study is to identify novel HIV-1 integrase (IN) inhibitors. Here, shape-based screening and QSAR have been successfully implemented to identify the novel inhibitors for HIV-1 IN, and in silico validation is performed by docking studies. The 2D QSAR model of benzodithiazine derivatives was built using genetic function approximation (GFA) method with good internal (cross-validated r(2) = 0.852) and external prediction (). Best docking pose of highly active molecule of the benzodithiazine derivatives was used as a template for shape-based screening of ZINC database. Toxicity prediction was also performed using Deductive Estimation of Risk from Existing Knowledge (DEREK) program to filter non-toxic molecules. Inhibitory activities of screened non-toxic molecules were predicted using derived QSAR models. Active, non-toxic screened molecules were also docked into the active site of HIV-1 IN using AutoDock and dock program. Some molecules docked similarly as highly active molecule of the benzodithiazine derivatives. These molecules also followed the same docking interactions in both the programs. Finally, four benzodithiazine derivatives were identified as novel HIV-1 integrase inhibitors based on QSAR predictions and docking interactions. ADME properties of these molecules were also computed using Discovery Studio.
Asunto(s)
Inhibidores de Integrasa VIH/química , Inhibidores de Integrasa VIH/farmacología , Integrasa de VIH/metabolismo , VIH-1/enzimología , Relación Estructura-Actividad Cuantitativa , Animales , Sitios de Unión , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/enzimología , Integrasa de VIH/química , Inhibidores de Integrasa VIH/toxicidad , VIH-1/efectos de los fármacos , Humanos , Modelos Biológicos , Modelos Moleculares , Unión Proteica , Tiazinas/química , Tiazinas/farmacología , Tiazinas/toxicidadRESUMEN
The activity of raltegravir and 4 other integrase inhibitors (MK-2048, L870,810, IN2, and IN5) was investigated in primary human macrophages, PBMC and C8166-lymphocytic T cells, in order to determine their relative potency and efficacy in different cellular systems of HIV infection. Raltegravir showed better protective efficacy in all cell types; MK-2048, L870,810 and IN5 showed a potent anti-HIV-1 activity in macrophages, while in lymphocytes only MK-2048 and L870,810 showed an inhibitory effect comparable to raltegravir. IN2 was a poorly effective anti-HIV-1 compound in all cellular systems. All effective integrase inhibitors exhibited a potent antiviral activity against both X4 and R5 HIV-1 strains. In general, raltegravir, MK-2048, L870,810 and IN5 showed anti HIV activity similar or slightly higher in macrophages compared to PBMC and C8166 T cells: for MK-2048, the EC(50) was 0.4, 0.9, 11.5 nM in macrophages, in PBMCs and T cells, respectively; for L870,810, the EC(50) was 1.5, 14.3, and 10.6 nM, respectively; for IN5 the EC(50) was 0.5, 13.7, and 5.7 nM, respectively.
Asunto(s)
Inhibidores de Integrasa VIH/farmacología , VIH-1/efectos de los fármacos , Linfocitos/virología , Macrófagos/virología , Apoptosis , Células Cultivadas , Proteína p24 del Núcleo del VIH/análisis , Inhibidores de Integrasa VIH/toxicidad , VIH-1/crecimiento & desarrollo , Humanos , Pruebas de Sensibilidad MicrobianaRESUMEN
HIV-1 integrase is one of three enzymes encoded by the HIV genome and is essential for viral replication, and HIV-1 IN inhibitors have emerged as a new promising class of therapeutics. Recently, we reported the discovery of azaindole hydroxamic acids that were potent inhibitors of the HIV-1 IN enzyme. N-Methyl hydroxamic acids were stable against oxidative metabolism, however were cleared rapidly through phase 2 glucuronidation pathways. We were able to introduce polar groups at the ß-position of the azaindole core thereby altering physical properties by lowering calculated log D values (c Log D) which resulted in attenuated clearance rates in human hepatocytes. Pharmacokinetic data in dog for representative compounds demonstrated moderate oral bioavailability and reasonable half-lives. These ends were accomplished without a large negative impact on enzymatic and antiviral activity, thus suggesting opportunities to alter clearance parameters in future series.
Asunto(s)
Inhibidores de Integrasa VIH/química , Integrasa de VIH/química , VIH-1/enzimología , Ácidos Hidroxámicos/química , Indoles/química , Administración Oral , Animales , Perros , Integrasa de VIH/metabolismo , Inhibidores de Integrasa VIH/farmacocinética , Inhibidores de Integrasa VIH/toxicidad , Semivida , Hepatocitos/efectos de los fármacos , Humanos , Ácidos Hidroxámicos/farmacocinética , Ácidos Hidroxámicos/toxicidad , Relación Estructura-ActividadRESUMEN
Previously, we discovered linomide analogues as novel HIV-1 integrase (IN) inhibitors. Here, to make possible structure-activity relationships, we report on the design and synthesis of a series of substituted dihydroquinoline-3-carboxylic acids. The crystal structure of the representative compound 2c has also been solved. Among the eight new analogues, 2e showed a potency in inhibiting IN strand transfer catalytic activity similar to the reference diketo acid inhibitor L-731,988 (IC(50)=0.9 microM vs. 0.54 microM, for 2e and L-731,988, respectively). Furthermore, none of the compounds showed significant cytotoxicity in two tested cancer cell lines. These compounds represent an interesting prototype of IN inhibitors, potentially involved in a metal chelating mechanism, and further optimization is warranted.
Asunto(s)
Ácidos Carboxílicos/síntesis química , Inhibidores de Integrasa VIH/síntesis química , Integrasa de VIH/química , Quinolinas/síntesis química , Ácidos Carboxílicos/química , Ácidos Carboxílicos/toxicidad , Línea Celular Tumoral , Cristalografía por Rayos X , Diseño de Fármacos , Integrasa de VIH/metabolismo , Inhibidores de Integrasa VIH/química , Inhibidores de Integrasa VIH/toxicidad , Humanos , Concentración 50 Inhibidora , Conformación Molecular , Quinolinas/química , Quinolinas/toxicidad , Relación Estructura-ActividadRESUMEN
The human immunodeficiency virus type 1 (HIV-1) integrase (IN) protein is an emerging target for the development of anti-HIV drugs. We recently described a new approach for inhibiting IN by "shiftides"--peptides that inhibit the protein by shifting its oligomerization equilibrium from the active dimer to the inactive tetramer. In this study, we used the yeast two-hybrid system with the HIV-1 IN as a bait and a combinatorial peptide aptamer library as a prey to select peptides of 20 amino acids that specifically bind IN. Five non-homologous peptides, designated as IN-1 to IN-5, were selected. ELISA studies confirmed that IN binds the free peptides. All the five peptides interact with IN with comparable affinity (K(d approximately )10 microM), as was revealed by fluorescence anisotropy studies. Only one peptide, IN-1, inhibited the enzymatic activity of IN in vitro and the HIV-1 replication in cultured cells. In correlation, fluorescence anisotropy binding experiments revealed that of the five peptides, only the inhibitory IN-1 inhibited the DNA binding of IN. Analytical gel filtration experiments revealed that only the IN-1 and not the four other peptides shifted the oligomerization equilibrium of IN towards the tetramer. Thus, the results show a distinct correlation between the ability of the selected peptides to inhibit IN activity and that to shift its oligomerization equilibrium.
Asunto(s)
Técnicas Químicas Combinatorias , Inhibidores de Integrasa VIH/farmacología , Integrasa de VIH/metabolismo , Péptidos/farmacología , Secuencia de Aminoácidos , Aptámeros de Péptidos/metabolismo , Muerte Celular/efectos de los fármacos , Permeabilidad de la Membrana Celular/efectos de los fármacos , Integrasa de VIH/química , Integrasa de VIH/fisiología , Inhibidores de Integrasa VIH/química , Inhibidores de Integrasa VIH/toxicidad , Células HeLa , Humanos , Cinética , Linfocitos/efectos de los fármacos , Linfocitos/virología , Datos de Secuencia Molecular , Péptidos/química , Péptidos/toxicidad , Unión Proteica/efectos de los fármacos , Estructura Cuaternaria de Proteína , Factores de Tiempo , Técnicas del Sistema de Dos Híbridos , Replicación Viral/efectos de los fármacosRESUMEN
Integrase inhibitors are a new therapeutic modality against HIV. Raltegravir is the first integrase inhibitor to have been approved by the health authorities for human use. This drug acts by inhibiting the HIV enzyme that catalyzes integration of the virus inside the genome of the host cell. In the host cell, there is no homologue to viral integrase and consequently the potential toxicity of this drug is probably low. The results of safety studies in animal models have shown that the recommended dose in humans is lower than the dose below which no secondary effects are observed. Studies of genotoxicity and carcinogenicity, as well as of fertility and embryo development, have been negative to date. During clinical trials, raltegravir has been shown to have a very good safety profile, with few adverse effects, which were mild-to-moderate and similar to those of the comparator. The most notable were diarrhea, nausea and headache. The lipid profile of raltegravir was better than that of efavirenz. In view of the above, the risk-benefit ratio for raltegravir is positive.
Asunto(s)
Infecciones por VIH/tratamiento farmacológico , Inhibidores de Integrasa VIH/efectos adversos , Integrasa de VIH/efectos de los fármacos , Pirrolidinonas/efectos adversos , Anomalías Inducidas por Medicamentos/etiología , Animales , Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Ensayos Clínicos como Asunto/estadística & datos numéricos , Perros , Evaluación Preclínica de Medicamentos , Desarrollo Embrionario/efectos de los fármacos , Femenino , Enfermedades Gastrointestinales/inducido químicamente , Inhibidores de Integrasa VIH/uso terapéutico , Inhibidores de Integrasa VIH/toxicidad , Cefalea/inducido químicamente , Humanos , Masculino , Ratones , Pruebas de Mutagenicidad , Dolor/inducido químicamente , Embarazo , Pirrolidinonas/uso terapéutico , Pirrolidinonas/toxicidad , Conejos , Raltegravir Potásico , RatasRESUMEN
Virtual screening docking-based approach has been employed in order to select novel HIV-1 integrase (IN) potential inhibitors in large databases. Toxicity, metabolism and drug-like properties have been analyzed for the most promising compounds, using computational chemistry techniques. Results were compared and discussed with that obtained for a known HIV-1 (IN) inhibitor reported in the literature.
Asunto(s)
Inhibidores de Integrasa VIH/farmacocinética , Integrasa de VIH/efectos de los fármacos , Animales , Simulación por Computador , Bases de Datos Factuales , Sistemas de Liberación de Medicamentos , Diseño de Fármacos , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/fisiopatología , Integrasa de VIH/metabolismo , Inhibidores de Integrasa VIH/farmacología , Inhibidores de Integrasa VIH/toxicidad , HumanosRESUMEN
Shionogi and GlaxoSmithKline, as the joint venture company Shionogi-GlaxoSmithKline Pharmaceuticals, is developing S-1360, an HIV integrase inhibitor as a potential treatment for HIV infection. As of October 2002, phase II trials were ongoing and launch is expected in 2004/2005.
Asunto(s)
Fármacos Anti-VIH/farmacología , Infecciones por VIH/tratamiento farmacológico , Inhibidores de Integrasa VIH/farmacología , Fármacos Anti-VIH/efectos adversos , Fármacos Anti-VIH/metabolismo , Fármacos Anti-VIH/uso terapéutico , Fármacos Anti-VIH/toxicidad , Ensayos Clínicos Fase I como Asunto , Ensayos Clínicos Fase II como Asunto , Furanos , Infecciones por VIH/virología , Inhibidores de Integrasa VIH/efectos adversos , Inhibidores de Integrasa VIH/metabolismo , Inhibidores de Integrasa VIH/uso terapéutico , Inhibidores de Integrasa VIH/toxicidad , Humanos , TriazolesRESUMEN
The human immunodeficiency virus type 1 (HIV-1) is a major health problem worldwide. In this study, 17 analogues of L-chicoric acid, a potent inhibitor of HIV integrase, were studied. Of these analogues, five submicromolar inhibitors of integrase were discovered and 13 compounds with activity against integrase at less than 10 microM were identified. Six demonstrated greater than 10-fold selectivity for HIV replication over cellular toxicity. Ten analogues inhibited HIV replication at nontoxic concentrations. Alteration of the linkages between the two bis-catechol rings, including the use of amides, mixed amide esters, cholate, and alkyl bridges, was explored. Amides were as active as esters but were more toxic in tissue culture. Alkyl and cholate bridges were significantly less potent against HIV-1 integrase in vitro and were inactive against HIV-1 replication. Two amino acid derivates and one digalloylderivative of L-chicoric acid (L-CA) showed improved selectivity over L-CA against integration in cell culture. These data suggest that in addition to the bis-catechols and free carboxylic acid groups reported previously, polar linkages are important constituents for optimal activity against HIV-1 integrase and that new derivatives can be developed with increased specificity for integration over HIV entry in vivo.
Asunto(s)
Ácidos Cafeicos , Ácido Clorogénico/análogos & derivados , Ácido Clorogénico/síntesis química , Inhibidores de Integrasa VIH/síntesis química , VIH-1/efectos de los fármacos , Tartratos/síntesis química , Benzoatos/síntesis química , Benzoatos/farmacología , Benzoatos/toxicidad , Supervivencia Celular/efectos de los fármacos , Ácido Clorogénico/farmacología , Ácido Clorogénico/toxicidad , Relación Dosis-Respuesta a Droga , Inhibidores de Integrasa VIH/farmacología , Inhibidores de Integrasa VIH/toxicidad , Humanos , Hidrólisis , Relación Estructura-Actividad , Succinatos/síntesis química , Succinatos/farmacología , Succinatos/toxicidad , Tartratos/farmacología , Tartratos/toxicidad , Replicación Viral/efectos de los fármacosRESUMEN
Integration is a required step in HIV replication, but as yet no inhibitors of the integration step have been developed for clinical use. Many inhibitors have been identified that are active against purified viral-encoded integrase protein; of these, many contain a catechol moiety. Though this substructure contributes potency in inhibitors, it is associated with toxicity and so the utility of catechol-containing inhibitors has been questioned. We have synthesized and tested a systematic series of derivatives of a catechol-containing inhibitor (1) with the goal of identifying catechol isosteres that support inhibition. We find that different patterns of substitution on the aromatic ring suffice for inhibition when Mn(2+) is used as a cofactor. Importantly, the efficiency is different when Mg(2+), the more likely in vivo cofactor, is used. These data emphasize the importance of assays with Mg(2+) and offer new catechol isosteres for use in integrase inhibitors.
Asunto(s)
Catecoles/química , Catecoles/síntesis química , Catecoles/farmacología , Inhibidores de Integrasa VIH/síntesis química , Inhibidores de Integrasa VIH/farmacología , VIH-1/efectos de los fármacos , Compuestos de Espiro/química , Antivirales/síntesis química , Antivirales/farmacología , Antivirales/toxicidad , Catecoles/toxicidad , Cationes Bivalentes , Supervivencia Celular/efectos de los fármacos , Inhibidores de Integrasa VIH/toxicidad , Células HeLa/efectos de los fármacos , Humanos , Enlace de Hidrógeno , Magnesio/farmacología , Manganeso/farmacología , Estructura Molecular , Virus del Molusco Contagioso/enzimología , Relación Estructura-Actividad , Inhibidores de Topoisomerasa IRESUMEN
HIV-1 integrase is an attractive target for anti-retroviral chemotherapy, but to date no clinically useful inhibitors have been developed. We have screened diverse marine natural products for compounds active against integrase in vitro and found a series of ascidian alkaloids, the lamellarins, that show selective inhibition. A new member of the family named lamellarin alpha 20-sulfate (1), the structure of which was determined from spectroscopic data, displayed the most favorable therapeutic index. The site of action of lamellarin alpha 20-sulfate on the integrase protein was mapped by testing activity against deletion mutants of integrase. Inhibition of isolated catalytic domain was detectable though weaker than inhibition of full length integrase; possibly lamellarin alpha 20-sulfate binds a site composed of multiple integrase domains. Lamellarin alpha 20-sulfate also inhibited integration in vitro by authentic HIV-1 replication intermediates isolated from infected cells. Lamellarin alpha 20-sulfate was tested against wild type HIV using the MAGI indicator cell assay and found to inhibit early steps of HIV replication. To clarify the inhibitor target, we tested inhibition against an HIV-based retroviral vector bearing a different viral envelope. Inhibition was observed, indicating that the HIV envelope cannot be the sole target of lamellarin alpha 20-sulfate in cell culture. In addition, these single round tests rule out action against viral assembly or budding. These findings provide a new class of compounds for potential development of clinically useful integrase inhibitors.
Asunto(s)
Cumarinas/aislamiento & purificación , Inhibidores de Integrasa VIH/aislamiento & purificación , Integrasa de VIH/metabolismo , VIH-1/efectos de los fármacos , Compuestos Heterocíclicos de 4 o más Anillos , Isoquinolinas , Pirroles/aislamiento & purificación , Urocordados/química , Animales , Línea Celular , Cumarinas/química , Cumarinas/farmacología , Cumarinas/toxicidad , Desoxirribonucleasa HindIII/antagonistas & inhibidores , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/aislamiento & purificación , Inhibidores Enzimáticos/farmacología , Inhibidores de Integrasa VIH/química , Inhibidores de Integrasa VIH/farmacología , Inhibidores de Integrasa VIH/toxicidad , VIH-1/enzimología , Células HeLa , Humanos , Concentración 50 Inhibidora , Virus del Molusco Contagioso/enzimología , Pirroles/química , Pirroles/farmacología , Pirroles/toxicidad , Inhibidores de Topoisomerasa I , Replicación Viral/efectos de los fármacosRESUMEN
On the basis of the fact that several polynucleotidyl transferases, related to HIV integrase, contain in their active site two divalent metal cations, separated by ca. 4 A, new potential HIV integrase inhibitors were designed, in which a quinoline substructure is linked to an aryl nucleus possessing various hydroxy substitution patterns, by means of an ethylenic spacer. Although the most active compounds contain the catechol structure, this group is not essential for the activity, since compound 21 that lacks such a moiety is a potent drug, implicating the presence of a different pharmacophore. The most promising styrylquinolines thus synthesized inhibit HIV-1 integrase in vitro at micromolar or submicromolar concentrations and block HIV replication in CEM cells, with no significant cellular toxicity in a 5-day period assay. These inhibitors are active against integrase core domain-mediated disintegration, suggesting that fragment 50-212 is their actual target. These new styrylquinolines may provide lead compounds for the development of novel antiretroviral agents for AIDS therapeutics, based upon inhibition of HIV integrase. They might also be used in the elucidation of the mechanism of inhibition of this enzyme; e.g., they could serve as candidates for cocrystallization studies with HIV integrase.